Company Overview of GlycoGenesys Inc.
On December 30, 2009, GlycoGenesys, Inc. went out of business as per its Chapter 7 liquidation filing under bankruptcy. GlycoGenesys, Inc. engages in the research and development of carbohydrate-based products, as well as related technologies in the area of oncology. Its lead product candidate includes GCS-100, a phase II clinical trial product, which would be used for the treatment of solid tumors and bloodborne cancers. The company was founded in 1987. It was formerly known as IGG International, Inc. and changed its name to SafeScience, Inc. in 1998; and then to GlycoGenesys, Inc. in 2001. GlycoGenesys is headquartered in Boston, Massachusetts.
Park Square Building
31 St James Avenue 8th Floor
Boston, MA 02116
Founded in 1987
Key Executives for GlycoGenesys Inc.
GlycoGenesys Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
|3D Biomatrix Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Only a company representative may request an update for the company profile. Documentation will be required.
To contact GlycoGenesys Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.